This is a working overview of angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-06. Anything still debated is marked as such rather than presented as settled.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
| Property | Value | Notes |
|---|---|---|
| Primary reported target | Hepatocyte growth factor/c-Met signaling | Findings mainly from cell and animal studies. |
| Related endogenous peptide | Angiotensin IV | Dihexa is described as a stabilized analog. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for purity assessment. |
| Identity confirmation | Mass spectrometry | Provides a molecular mass check. |
| Regulatory status | Not approved for human use | Sold as a research chemical in many jurisdictions. |
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Cognitive behavioral therapy (CBT) developed from the combination of cognitive therapy and rational emotive behavior therapy, both of which grew out of cognitive psychology and behaviorism. CBT is based on the theory that how we think (cognition), how we feel (emotion), and how we act (behavior) are related and interact together in complex ways. In this perspective, certain dysfunctional ways of interpreting and appraising the world (often through schemas or beliefs) can contribute to emotional distress or result in behavioral problems. The object of many cognitive behavioral therapies is to discover and identify the biased, dysfunctional ways of relating or reacting and through different methodologies help clients transcend these in ways that will lead to increased well-being. There are many techniques used, such as systematic desensitization, socratic questioning, and keeping a cognition observation log. Modified approaches that fall into the category of CBT have also developed, including dialectic behavior therapy and mindfulness-based cognitive therapy. Behavior therapy is a tradition. It is researched with an evidence base. Its roots are in behaviorism. In behavior therapy, environmental events predict the way we think and feel. Our behavior sets up conditions for the environment to feedback back on it. Sometimes the feedback leads the behavior to increase- reinforcement and sometimes the behavior decreases- punishment. Oftentimes behavior therapists are called applied behavior analysts or behavioral health counselors.
== Measurement techniques == The choice of various conventional or in-situ analysis techniques affects the resolution, precision, detection limits and cost of monazite geochronology. The recent analytical progress in U-Th-Pb system in natural monazite has been mainly achieved by (1) Isotope Dilution Thermal Ionization Mass Spectrometry (ID-TIMS), (2) Secondary Ion Mass Spectrometry (SIMS), (3) Laser Ablation Inductively Coupled Plasma Mass Spectrometry (LA-ICP-MS) and (4) Electronic Microprobe Analyses (EMPA).
Widespread use Spironolactone — the first and most widely used member of this class Eplerenone — much more selective than spironolactone on target, but somewhat less potent and efficacious Uncommon use (to date) Canrenone and potassium canrenoate — very limited use Finerenone — nonsteroidal and more potent and selective than either eplerenone or spironolactone Some drugs also have antimineralocorticoid effects secondary to their main mechanism of actions. Examples include progesterone, drospirenone, gestodene, metribolone, and benidipine.
=== January === 1 January Helen Hogan, educator (Hillmorton High School, WEA), editor of poetry anthologies, and Māori studies scholar (born 1923). Lyn Fleming, Police senior sergeant and first policewoman in New Zealand to be killed in the line of duty (born 1963). 2 January – Lex Clark, Olympic rower (1964) (born 1943). 3 January Kate Coolahan, commercial artist, fashion illustrator, printmaker, and design educator (Wellington Polytechnic) (born 1929). Dame Tariana Turia, politician, Labour list MP (1996–2002), MP for Te Tai Hauāuru (2002–2014), co-leader of the Māori Party (2004–2014), Minister for the Community and Voluntary Sector (2003–2004, 2008–2011), Minister for Disability Issues (2009–2014), Minister for Whānau Ora (2010–2014) (born 1944). 5 January Philippa Blair, artist (born 1945). Lou Robinson, structural engineer and heritage advocate (born 1943). 7 January – Arthur Pomeroy, classical scholar (Victoria University of Wellington), chess player and administrator (born 1953). 18 January – Russell Marshall, politician and diplomat, MP for Wanganui (1972–1990), Minister of Education (1984–1987), Minister of Foreign Affairs (1987–1990), chancellor of Victoria University of Wellington (2000–2002), High Commissioner to the United Kingdom (2002–2005) (born 1936). 19 January – David Johnston, disaster researcher (Massey University) (born 1966). 20 January – Richard Hipa, Niuean public servant and politician, Secretary of Government (2008–2017), Member of the Niue Assembly (2020–2023) (born 1957). 21 January Diana Beaglehole, historian (born 1938).
On the other hand, if the starting material is enough to develop more complete protocol, the amount of work to reach the separation goal depends on the available sample information and target molecule properties. Limits to development of purification protocols many times depends on the source of the substance to be purified, whether from natural sources (harvested tissues or organisms, for example), recombinant sources (such as using prokaryotic or eukaryotic vectors in their respective expression systems), or totally synthetic sources. No chromatographic techniques provide 100% yield of active material and overall yields depend on the number of steps in the purification protocol. By optimizing each step for the intended purpose and arranging them that minimizes inter step treatments, the number of steps will be minimized. A typical multistep purification protocol starts with a preliminary capture step which often utilizes ion exchange chromatography (IEC). The media (stationary phase) resin consists of beads, which range in size from being large (good for fast flow rates and little to no sample clarification at the expense of resolution) to small (for best possible resolution with all other factors being equal). Short and wide column geometries are amenable to high flow rates also at the expense of resolution, typically because of lateral diffusion of sample on the column. For techniques such as size exclusion chromatography to be useful, very long, thin columns and minimal sample volumes (maximum 5% of column volume) are required.
Sources: en.wikipedia.org
, respectively. Their ratio is not equal to the equilibrium constant, which implies that thermodynamics does not constrain the ratio of the maximal rates. This explains that enzymes can be much "better catalysts" (in terms of maximal rates) in one particular direction of the reaction. One can also derive the two Michaelis constants
The first one to systematically expand and correct the chemical potentials of Bohr's atomic theory was Walther Kossel in 1914 and in 1916. Kossel explained that in the periodic table new elements would be created as electrons were added to the outer shell. In Kossel's paper, he writes: This leads to the conclusion that the electrons, which are added further, should be put into concentric rings or shells, on each of which ... only a certain number of electrons—namely, eight in our case—should be arranged. As soon as one ring or shell is completed, a new one has to be started for the next element; the number of electrons, which are most easily accessible, and lie at the outermost periphery, increases again from element to element and, therefore, in the formation of each new shell the chemical periodicity is repeated. In a 1919 paper, Irving Langmuir postulated the existence of "cells" which we now call orbitals, which could each only contain eight electrons each, and these were arranged in "equidistant layers" which we now call shells. He made an exception for the first shell to only contain two electrons. The chemist Charles Rugeley Bury suggested in 1921 that eight and eighteen electrons in a shell form stable configurations. Bury proposed that the electron configurations in transitional elements depended upon the valence electrons in their outer shell. He introduced the word transition to describe the elements now known as transition metals or transition elements.
This California-based project is working to combat the negative perception with mental health and reduce the stigma associated with it. While social media can benefit mental health, it can also lead to deterioration if not managed properly. Limiting social media intake is beneficial. Studies report that patients in mental health care who can access and read their Electronic Health Records (EHR) or Open Notes online experience increased understanding of their mental health, feeling in control of their care, and enhanced trust in their clinicians. Patients' also reported feelings of greater validation, engagement, remembering their care plan, and acquiring a better awareness of potential side effects of their medications, when reading their mental health notes. Other common experiences were that shared mental health notes enhance patient empowerment and augment patient autonomy. Furthermore, recent studies have shown that social media is an effective way to draw attention to mental health issues. By collecting data from Twitter, researchers found that social media presence is heightened after an event relating to behavioral health occurs. Researchers continue to find effective ways to use social media to bring more awareness to mental health issues through online campaigns in other sites such as Facebook and Instagram.
Drug recycling is a relatively new concept, but in some places it happens. Sometimes, an individual or organization will have valuable medicine which they do not intend to use. If that medication could be used by other people before its expiration, then sometimes, interested parties discuss drug recycling to transfer ownership of the drugs away from the party which will not use them to the party which needs them. In such discussions, anyone considering the transfer of drugs will also consider if drugs could be used before their expiration. In the United States, there is a growing movement for medication reclamation and reuse, particularly for high-cost specialty drugs such as oral chemotherapies. This practice is increasingly viewed as an opportunity to reduce pharmaceutical waste and help patients who cannot afford necessary medications. In the U.S., programs for drug reclamation and donation are regulated on a state-by-state basis, with some states allowing the donation and/or dispensing of approved unused prescriptions. Tennessee law, for example, permits programs based in the state to accept donations of approved unused prescriptions from individuals and clinics from anywhere in the United States. It also allows dispensing of approved donated medications to patients in need. Dispensing donated medications is currently allowed, in various forms, in 42 U.S. states.
=== Radioactive isotopes === The existence of isotopes was first suggested in 1913 by the radiochemist Frederick Soddy, based on studies of radioactive decay chains that indicated about 40 different species referred to as radioelements (i.e. radioactive elements) between uranium and lead, although the periodic table only allowed for 11 elements between lead and uranium inclusive. Several attempts to separate these new radioelements chemically had failed. For example, Soddy had shown in 1910 that mesothorium (later shown to be 228Ra), radium (226Ra, the longest-lived isotope), and thorium X (224Ra) are impossible to separate. Attempts to place the radioelements in the periodic table led Soddy and Kazimierz Fajans independently to propose their radioactive displacement law in 1913, to the effect that alpha decay produced an element two places to the left in the periodic table, whereas beta decay emission produced an element one place to the right. Soddy recognized that emission of an alpha particle followed by two beta particles led to the formation of an element chemically identical to the initial element but with a mass four units lighter and with different radioactive properties. Soddy proposed that several types of atoms (differing in radioactive properties) could occupy the same place in the table. For example, the alpha-decay of uranium-235 forms thorium-231, whereas the beta decay of actinium-230 forms thorium-230.
Sources: en.wikipedia.org
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.
Reverse-phase high-performance liquid chromatography is commonly used to assess purity. Mass spectrometry is used to confirm molecular identity. These methods are typical for synthetic peptides and research chemicals.
Dihexa is not approved as a drug in major jurisdictions. It is often sold as a research chemical, which is not the same as a medicine. Its legal status can vary by country and may change.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.